Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV, a foreign private issuer, for the month of April 2022. The filing, dated April 27, 2022, incorporates by reference a press release issued on April 26, 2022 (Exhibit 99.1). The registrant is incorporated in Belgium and files annual reports on Form 20-F. Note: The request metadata references "Lakefront Biotherapeutics NV," but the filing text explicitly identifies the registrant as Galapagos NV.
Key Financial Metrics
The filing text provided does not contain specific financial data. It serves as a cover document to incorporate a press release by reference. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text.
Material Changes
The filing text does not disclose specific material changes to financial position or operations. It indicates that a material event or announcement was made via the attached press release, but the content of that announcement is not included in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors. It states that the information in the attached press release is incorporated into various Registration Statements (Forms F-3 and S-8), but the substance of that information is not available in the source text.
Investor Verification Checklist
- Verify the content of the press release dated April 26, 2022 (Exhibit 99.1), as the filing text only references it without summarizing its details.
- Confirm the registrant identity is Galapagos NV, not Lakefront Biotherapeutics NV, based on the filing header.
- Review the referenced Registration Statements (File Nos. 333-230639 and various S-8 filings) for context on how the press release information impacts outstanding securities.
- Check subsequent filings for the actual financial metrics and operational updates implied by the April 26 press release.